2026-11-092026-11-09https://scholars.csmu.edu.tw/handle/123456789/38815Metastasis of cancer cells, a primary cause of cancer death and a multiple and intricate processes, may complicate the clinical management and lead to a poor prognosis for cancer patients and has tremendous physical or economical impact to patients or communities. In general, metastasis of cancer cells involves multiple processes and various cytophysiological changes, including changed adhesive capability between cells and extracellular matrix (ECM) and damaged intercellular interaction. Degradation of ECM by cancer cells via protease, such as serine proteinase, matrix metalloproteinases (MMPs), cathepsins, and plasminogen activators (PAs), may lead to the separation of intercellular matrix to promote the mobility of cancer cells and eventually lead to metastasis. Among these involved proteases, MMP-2, MMP-9 and u-PA are the most vital ones for degradation of base membrane and therefore deeply involved in cancer invasion and metastasis. We have demonstrated that silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2 and also inhibits MG-63 cell-matrix adhesion by aggregating filamentous actin and changing cellular shape. We also found that alendronate could induce apoptosis in human osteosarcoma cells (U2OS, HOS and MG-63) does-dependently and zoledronic acid could inhibit the cell variability in U2OS and HOS cells, but not in MG-63 cells. Therefore, in the first year of this study, we propose to (1) analyze and compare the effects of different bisphosphonates (alendronate, ibandronate and zoledronic acid) on cell viability of different osteosarcoma cells (MG-63, U2OS and HOS) using MTT assay and trypan blue dye exclusion assay; (2) exam the colony formation of osteosarcoma cells (MG-63, U2OS and HOS) after different bisphosphonates (alendronate, ibandronate and zoledronic acid) treatment; (3) investigate the changes in the cell cycle of different osteosarcoma cells (MG-63, U2OS and HOS) after different bisphosphonates (alendronate, ibandronate and zoledronic acid) treatment using flow cytometry; (4) confirm the apoptotic effect of different bisphosphonates (alendronate, ibandronate and zoledronic acid) on different osteosarcoma cells (MG-63, U2OS and HOS) using DNA fragmentation assay, DAPI stain, TUNEL, and Annexin V-conjugated Alexafluor 488; and (5) further demonstrate the mechanism involved in reduced invasion by lower doses (not to induce cell apoptosis or cytotoxicity) of different bisphosphonates (alendronate, ibandronate and zoledronic acid), including changed adhesive capability and invasive ability and ECM degraded proteinase (MMPs and u-PA) activities. Then, in the second year of this study, we aim to (1) analyze and compare cell cycle related kinases cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors (CDKIs) after different bisphosphonates (alendronate, ibandronate and zoledronic acid) treatment in different osteosarcoma cells (MG-63, U2OS and HOS); (2) investigate the binding ability between CDKs and CDKIs in different osteosarcoma cells (MG-63, U2OS and HOS) after different bisphosphonates (alendronate, ibandronate and zoledronic acid) treatment using immunoprecipitated assay; (3) demonstrate the effect of different bisphosphonates (alendronate, ibandronate and zoledronic acid) on apoptosis related proteins in different osteosarcoma cells (MG-63, U2OS and HOS); (4) determine the effect of the lower doses of bisphosphonates (alendronate, ibandronate and zoledronic acid) on migration, invasion and adhesion related genes expression; (5) further detect the lower doses of different bisphosphonates (alendronate, ibandronate and zoledronic acid) not to induce the apoptosis or cytotoxicity in different osteosarcoma cells (MG-63, U2OS and HOS) on the signal transduction pathways of adhesion, invasion and migration; and (6) test the lower doses of different bisphosphonates (alendronate, ibandronate and zoledronic acid) not to induce the apoptosis or cytotoxicity in different osteosarcoma cells (MG-63, U2OS and HOS) on the regulation of transcription factors via western blotting and EMSA assay to determine the transactivity of these transcription factors and binding activity with its target binding sequence. Finally, in the third year of this study, we aim to (1) clone the promoter region of MMP-2, -9, u-PA, TIMPs, PAIs and create promoter constructs driving luciferase to detect the effect of different bisphosphonates (alendronate, ibandronate and zoledronic acid) treatment on regulation of selected gene expression via luciferase assay; (2) determine and compare the effect of different bisphosphonates (alendronate, ibandronate and zoledronic acid) on tumor growth via a BALB/c nude mice model, (3) analyze the effect of different bisphosphonates (alendronate, ibandronate and zoledronic acid) on angiogenesis process in vivo, (4) investigate tumor growth of different osteosarcoma cells (U2OS、MG-63 及 HOS) in vivo via cancer cell xenografted nude mice model, and (5) finally analyze the effect of different bisphosphonates (alendronate, ibandronate and zoledronic acid) on migration/invasion related genes via a BALB/c nude mice model by immunohistochemistry assay.癌細胞轉移(metastasis)是癌症導致死亡以及治療複雜度提昇的主要原因; 而 癌細胞轉移已知與多種細胞生理改變密切相關,如改變癌細胞與胞外基質 (extracellular matrix,ECM)間及基底膜(basement membrane)的貼附(adhesion) 能力,破壞細胞間交互作用(intercellular interaction)的力量等。癌細胞之所以能 轉移主要是透過癌細胞分泌蛋白分解酵素,如:serine proteinase、基質金屬蛋白水 解酶(matrix metalloproteinases ,MMPs )、cathepsins 以及胞漿素原活化劑 (plasminogen activators,PAs)分解胞外基質,最後導致細胞間基質分離和基底膜 的分解,進而使癌細胞移動(migration)及侵襲(invasion)提昇。而在這些水解 酵素中,MMP-2、MMP-9 及尿激酶型胞漿素原活化劑(urokinase-type PA,u-PA) 在癌細胞移動及侵襲過程中扮演著最重要的角色。 雙磷酸鹽類藥物,如alendronate、ibandronate 及zoledronic acid,已經廣泛使 用於臨床上來治療骨質疏鬆症。然而,這幾年來,有許多文獻指出這類藥物除了在 治療骨質疏鬆症外,如前列腺癌、乳癌、肺癌等惡性腫瘤骨轉移及高血鈣也是常使 用雙磷酸鹽類。因此,雙磷酸鹽類藥物用於治療許多骨疾病的重要地位是無庸置疑 的。雖然雙磷酸鹽類可抑制惡性腫瘤細胞生長能力,甚至高劑量時可促使惡性腫瘤 細胞凋亡的作用已經相當明確。但在不同的骨癌細胞中其化學防癌及抗癌作用之角 色上,如低劑量下雙磷酸鹽類可否影響MMPs family、plasmin、u-PA、組織型胞漿 素原活化劑(tissue-type PA,t-PA)或其抑制劑TIMPs、PA inhibitors(PAIs)之表 現或高劑量誘導不同骨癌細胞株的細胞凋亡方面,仍極少被研究。 我們曾發現類黃酮silibinin 會壓制人類骨癌MG-63 細胞的侵襲,它是藉由抑 制胞外訊息調節蛋白水解酶(ERK)依賴之c-Jun/活酶蛋白-1(AP-1)所誘導出的 MMP-2。於是我們以不同濃度的alendronate 處理不同的骨癌細胞株U2OS、MG-63 及HOS,發現此劑量對U2OS、MG-63 及HOS 的細胞生長有明顯的抑制。進一步 以不同濃度的zoledronic acid 處理不同的骨癌細胞株U2OS、MG-63 及HOS,發現 此劑量對U2OS 及HOS 的細胞生長有明顯的抑制,但對MG-63 卻沒有效果。 因此,本計畫第一年擬進行【1】利用MTT assay 與細胞計數實驗(trypan blue dye exclusion assay),探討不同的雙磷酸鹽類藥物,如:alendronate、ibandronate 及zoledronic acid 對不同骨癌細胞株(MG-63、U2OS 及HOS)存活率的影響;【2】 利用colony formation,觀察不同的雙磷酸鹽類藥物(alendronate、ibandronate 及 zoledronic acid)能否抑制多種不同骨癌細胞株(MG-63、U2OS 及HOS)形成colony 之能力;【3】以流式細胞儀(flow cytometry)測定細胞週期,探討不同的雙磷酸 鹽類藥物(alendronate、ibandronate 及zoledronic acid)對不同骨癌細胞株(MG-63、 U2OS 及HOS)其細胞週期的影響;【4】以DNA fragmentation assay、DAPI stain、 TUNEL、Annexin V-conjugated Alexafluor 488 用來分析不同的雙磷酸鹽類藥物 (alendronate、ibandronate 及zoledronic acid)是否能誘導不同骨癌細胞之凋謝死 亡;以及【5】利用migration/invasion assay、adhesion assay 及zymography 分析方 式完成不同的雙磷酸鹽類藥物(alendronate、ibandronate 及zoledronic acid)在低濃 度不影響其細胞存活率的情況下,對不同骨癌細胞株(MG-63、U2OS 及HOS), 其細胞移動、侵襲、貼附和轉移能力、基質分解相關蛋白酶活性的影響之分析。 本計畫第二年擬進行【1】利用western blot 探討不同的雙磷酸鹽類藥物 (alendronate、ibandronate 及zoledronic acid)對不同骨癌細胞株(MG-63、U2OS 及HOS)其與細胞週期相關的cyclins 和cyclin-dependent kinase inhibitors(CDKIs) 的影響;【2】利用immunoprecipitated(IP)的技術,探討不同的雙磷酸鹽類藥物 (alendronate、ibandronate 及zoledronic acid)是否會透過影響與細胞週期相關的 CDKs 分別與CDKIs 之結合情形;【3】以western blot 探討不同的雙磷酸鹽類藥物 (alendronate、ibandronate 及zoledronic acid)與細胞凋亡之相關蛋白表現;【4】以 RT-PCR 及real-time PCR 分析不同的雙磷酸鹽類藥物(alendronate、ibandronate 及 zoledronic acid)在低濃度不影響其細胞存活率的情況下,抑制不同骨癌細胞株 (MG-63、U2OS 及HOS)其migration/invasion 和adhesion 相關基因的影響;【5】 進一步探討不同的雙磷酸鹽類藥物(alendronate、ibandronate 及zoledronic acid)在 低濃度不影響其細胞存活率的情況下,抑制不同骨癌細胞株(MG-63、U2OS 及 HOS)其細胞移動、侵襲、貼附和轉移能力之蛋白酶分泌的相關訊息傳遞路徑的蛋 白變化;以及【6】以electrophoretic mobility shift assay(EMSA)、western blot 探 討不同的雙磷酸鹽類藥物(alendronate、ibandronate 及zoledronic acid)在低濃度不 影響其細胞存活率的情況下,是否抑制上述基因的相關轉錄因子表現,或與其target binding sequence 的結合能力。 本計畫第三年擬進行【1】選殖基質分解相關蛋白酶(MMP-2、MMP-9、u-PA、 TIMP-1 及PAI-1)的promoter region,構築luciferase/reporter gene plasmid(pGL3), 送入不同骨癌細胞株(MG-63、U2OS 及HOS)中,同時處理對目標基因有抑制效 果的雙磷酸鹽類藥物,以luciferase assay 分析雙磷酸鹽類藥物對個別基因promoter 的調控;【2】以免疫缺陷的小鼠(BALB/c nu/nu mice)接種人類不同骨癌細胞 (MG-63、U2OS 及HOS)癌瘤細胞,並處理不同的雙磷酸鹽類藥物(alendronate、 ibandronate 及zoledronic acid),分析老鼠其腫瘤大小、重量及其動物存活率的影 響;【3】利用免疫組織染色的方式,分析上述處理不同的雙磷酸鹽類藥物 (alendronate、ibandronate 及zoledronic acid)其腫瘤組織切片,觀察腫瘤相關因子 及一些血管新生之相關因子的影響;【4】利用in vivo 實驗將matrigel 混合VEGF 或FGF 處理的不同骨癌細胞株(MG-63、U2OS 及HOS),再處理不同的雙磷酸鹽 類藥物(alendronate、ibandronate 及zoledronic acid),種到C57BL/6 老鼠皮下,再 將matrigel 取出,觀察其抑制血管新生之能力;以及【5】利用不同接種方式,將 不同骨癌細胞(MG-63、U2OS 及HOS)接種至免疫缺陷的小鼠(BALB/c nu/nu mice) 的尾靜脈,並處理不同的雙磷酸鹽類藥物(alendronate、ibandronate 及zoledronic acid),分析其轉移至肺部之癌細胞colony 數目及組織切片,利用免疫組織染色的 方式觀察其migration/invasion 相關基因蛋白層次的影響,以評估其抑制細胞轉移 之能力。探討Alendronate, Ibandronate及Zoledronic Acid對不同骨癌細胞株轉移之抑制能力及誘導細胞凋亡的機制及其路徑之研究Project